Disease or Syndrome
FDA Approves Moderna’s RSV Vaccine, Marking Its Second Commercial Product
Moderna, RSV Vaccine, FDA Approval, mRNA Technology, Respiratory Syncytial Virus, COVID-19, Spikevax, mRESVIA
Bulevirtide: A Novel Treatment for Chronic Hepatitis Delta Virus Infection
Bulevirtide, Hepatitis Delta Virus (HDV), Chronic Infection, Antiviral Therapy, Clinical Trials, Efficacy, Safety
Breakthrough in Lupus Treatment: CAR T-Cell Therapy Shows Promising Results
CAR T-cell therapy, lupus, autoimmune disease, cancer treatment, immunology
Intellia Therapeutics Advances in Hereditary Angioedema Treatment with Durable One-Dose CRISPR Gene Editing Therapy
Intellia Therapeutics, Hereditary Angioedema (HAE), CRISPR Gene Editing, NTLA-2002, Single-Dose Treatment, Long-Term Data, Clinical Trials
Annexon Shares Soar as ANX005 Meets Primary Endpoint in Phase 3 Trial for Guillain-Barré Syndrome
Annexon, ANX005, Guillain-Barré Syndrome, Phase 3 Trial, Primary Endpoint, Disability Reduction, Share Price Surge
Structure Therapeutics’ Oral GLP-1 Achieves Comparable Weight Loss to Lilly’s Candidate
Structure Therapeutics, GLP-1, Obesity, Weight Loss, Lilly, Oral Candidate
Biotech Faces a Reckoning: The Challenges and Shifts in Cell Therapies
cell therapy, biotech, gene therapy, autoimmune diseases, manufacturing challenges, market acceptance, pharmaceutical industry
Takeda’s Orexin Narcolepsy Drug TAK-861 Poised for Phase III Trials After Promising Results
Takeda, TAK-861, narcolepsy, orexin receptor 2 agonist, Phase III trials, narcolepsy type 1, sleep disorders
Intellia Therapeutics Reports Promising Long-Term Data for Single-Dose HAE Therapy
Intellia Therapeutics, NTLA-2002, Hereditary Angioedema (HAE), CRISPR Gene Editing, Single-Dose Treatment, Long-Term Data
Lilly Strengthens Neuro Pipeline with $45M Deal for QurAlis’ Preclinical ALS and Dementia Treatment
Lilly, QurAlis, ALS, dementia, neurodegenerative diseases, UNC13A, splice-switching antisense oligonucleotide, QRL-204, neuro pipeline, preclinical treatment